ArticleFrontiers in medicine2022
Clinical Characteristics and Mortality of Non-tuberculous Mycobacterial Infection in Immunocompromised vs. Immunocompetent Hosts.
Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Prevalence ofFrontiers in microbiology · 2024Pooled it
- Article
- Mycobacterium cajalii sp. nov., a novel scotochromogenic rapid-growing nontuberculous mycobacterial species closely related to Mycobacterium servetii.Antonie van Leeuwenhoek · 2026Article
- Molecular Techniques for MTBC and NTM Differentiation: Diagnostic Accuracy of STANDARD™ M10 MTB/NTM and Potential Applications.Diagnostics (Basel, Switzerland) · 2026Article
- The rise of nontuberculous mycobacteria following MIGS and minimally invasive procedures.Annals of medicine and surgery (2012) · 2026Article
- Pathogenicity and virulence ofVirulence · 2025Review
- Distribution of nontuberculous Mycobacteria among presumptive drug resistance tuberculosis patients from a ministry of health drug resistance surveillance program, in western Kenya.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- Disseminated Mycobacterium avium complex infection presenting as superior vena cava syndrome in a patient with anti-interferon-gamma autoantibody: a case report.BMC infectious diseases · 2025Article
- Optimising non-pharmacological interventions in people with non-tuberculous mycobacterial pulmonary disease: a systematic review.ERJ open research · 2025Article
- The Underestimated Threat-Mycobacterium Genavense Infection: A Case Report.Infectious disease reports · 2025Article
- Lung Microenvironment Among Patients with Nontuberculous Mycobacterial Pulmonary Disease by Metagenomic Sequencing Technique.Biomedicines · 2025Article
- Disseminated nontuberculous mycobacterial infection in the context of interferon-gamma autoantibody syndrome: A case report and review of the literature.European journal of microbiology & immunology · 2025Article
- Clinical correlation study of non-tuberculous mycobacterial isolates from bronchoalveolar lavage fluid.AMB Express · 2025Article
- Extrapulmonary Comparisons BetweenInfection and drug resistance · 2025Review
- Toward better cures forClinical microbiology reviews · 2024Review
- Mortality Rate and Cause of Death in Adults with Extrapulmonary Nontuberculous Mycobacteria Infection, Denmark.Emerging infectious diseases · 2024Article
- Torquetenovirus from bronchoalveolar lavage fluid as a biomarker for lung infection among immunocompromised hosts.Biomarkers in medicine · 2024Article
- Treatment for non-tuberculous mycobacteria: challenges and prospects.Frontiers in microbiology · 2024Review
- Nontuberculosis mycobacteria (NTM) infections in patients with leukemia: a single center case series.Frontiers in medicine · 2024Article
- Dimethyl itaconate is effective in host-directed antimicrobial responses against mycobacterial infections through multifaceted innate immune pathways.Cell & bioscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunosuppression and host vulnerability play a key role in non-tuberculous mycobacteria (NTM) pathogenesis. The objective of this study was to compare the clinical characteristics and mortality of NTM infections in immunocompromised and immunocompetent patients. We used a retrospective dataset obtained from our large, tertiary, urban, teaching hospital which is the medical records of hospitalized patients with NTM infections between January 1, 2013 to December 31, 2020. The information including clinical manifestations, imaging, and NTM etiological data were obtained from the hospital's clinical data system. A total of 480 patients with NTM infections completed species identification. 118 hospitalized NTM patients who met ATS/IDSA NTM diagnostic criteria and had complete medical records were included in the study. The average age was 49.4 years, 57 (48.3%) were female, and 64 (54.2%) were immunosuppressed hosts. In our study, the most common species in order of frequency were:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.